Overview


Clinical Trials

Severe CHD

Wound Healing

 PAD


Pre-Clinical Research
Scientific Reports

   
CVBT Pre-Clinical Research  
 


We are now working to investigate FGF-1 for many different applications, and have initiated pre-clinical testing for the following:

·   FGF-1 and Stroke – the goal of our pre-clinical research is to assess the effects of our drug candidate, CVBT-141F, in reducing brain damage due to stroke
· FGF-1 and Osteoporosis – to date we have seen positive pre-clinical results of the effects of our drug candidate, CVBT-141G, in an animal model of bone growth
· Lumbar Ischemia – the study is being conducted by Vance Gardner, M.D. and the Orthopaedic Education and Research Institute of Southern California

 

 

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.









 

2/24/2009
CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial


1/8/2009
CVBT Opens Two Additional Sites for Its ACORD Phase II Heart Trial


12/11/2008
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial


11/25/2008
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease